These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23830291)

  • 1. Late and very late stent thrombosis in patients with second-generation drug-eluting stents.
    Huang KN; Grandi SM; Filion KB; Eisenberg MJ
    Can J Cardiol; 2013 Nov; 29(11):1488-94. PubMed ID: 23830291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of early versus late clopidogrel discontinuation on stent thrombosis following percutaneous coronary intervention with first- and second-generation drug-eluting stents.
    Loh JP; Torguson R; Pendyala LK; Omar A; Chen F; Satler LF; Pichard AD; Waksman R
    Am J Cardiol; 2014 Jun; 113(12):1968-76. PubMed ID: 24767975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.
    Yu X; Chen F; He J; Gao Y; Wu C; Luo Y; Zhang X; Zhang Y; Ren X; Lv S
    Coron Artery Dis; 2013 May; 24(3):217-23. PubMed ID: 23425771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents.
    Eisenberg MJ; Richard PR; Libersan D; Filion KB
    Circulation; 2009 Mar; 119(12):1634-42. PubMed ID: 19289638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimized duration of clopidogrel therapy following treatment with the Endeavor zotarolimus-eluting stent in real-world clinical practice (OPTIMIZE) trial: rationale and design of a large-scale, randomized, multicenter study.
    Feres F; Costa RA; Bhatt DL; Leon MB; Botelho RV; King SB; de Paula JE; Mangione JA; Salvadori D; Gusmão MO; Castello H; Nicolela E; Perin MA; Devito FS; Marin-Neto JA; Abizaid A
    Am Heart J; 2012 Dec; 164(6):810-6.e3. PubMed ID: 23194480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the incidence of late stent thrombosis after implantation of different drug-eluting stents in the real world coronary heart disease patients: three-year follow-up results.
    Chen JL; Gao LJ; Yang YJ; Li JJ; Qiao SB; Xu B; Huang JH; Yao M; Qin XW; Liu HB; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Gao RL
    Chin Med J (Engl); 2010 Apr; 123(7):778-81. PubMed ID: 20497663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The optimal discontinuation of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention with drug-eluting stents: A meta-analysis of randomized trials.
    Wang W; Liu J; Fang J; Liu Y; An T; Zou M; Cheng G
    Int J Cardiol; 2017 May; 235():73-86. PubMed ID: 28284499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of 36 reported cases of late thrombosis in drug-eluting stents placed in coronary arteries.
    Artang R; Dieter RS
    Am J Cardiol; 2007 Apr; 99(8):1039-43. PubMed ID: 17437724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type.
    Camenzind E; Boersma E; Wijns W; Mauri L; Rademaker-Havinga T; Ordoubadi FF; Suttorp MJ; Al Kurdi M; Steg PG;
    Eur Heart J; 2014 Aug; 35(29):1932-48. PubMed ID: 24627416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Généreux P; Rutledge DR; Palmerini T; Caixeta A; Kedhi E; Hermiller JB; Wang J; Krucoff MW; Jones-McMeans J; Sudhir K; Simonton CA; Serruys PW; Stone GW
    Circ Cardiovasc Interv; 2015 May; 8(5):. PubMed ID: 25940520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation (from the TYCOON [two-year ClOpidOgrel need] study).
    Tanzilli G; Greco C; Pelliccia F; Pasceri V; Barillà F; Paravati V; Pannitteri G; Gaudio C; Mangieri E
    Am J Cardiol; 2009 Nov; 104(10):1357-61. PubMed ID: 19892050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis.
    Palmerini T; Biondi-Zoccai G; Della Riva D; Mariani A; Sabaté M; Valgimigli M; Frati G; Kedhi E; Smits PC; Kaiser C; Genereux P; Galatius S; Kirtane AJ; Stone GW
    J Am Coll Cardiol; 2013 Aug; 62(6):496-504. PubMed ID: 23747778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duration of dual antiplatelet therapy after various drug-eluting stent implantation.
    Sharma A; Sharma SK; Vallakati A; Garg A; Lavie CJ; Mukherjee D; Marmur JD
    Int J Cardiol; 2016 Jul; 215():157-66. PubMed ID: 27116326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
    Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
    Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials.
    Palmerini T; Kirtane AJ; Serruys PW; Smits PC; Kedhi E; Kereiakes D; Sangiorgi D; Bacchi Reggiani L; Kaiser C; Kim HS; De Waha A; Ribichini F; Stone GW
    Circ Cardiovasc Interv; 2012 Jun; 5(3):357-64. PubMed ID: 22668554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents.
    Kandzari DE; Barker CS; Leon MB; Mauri L; Wijns W; Fajadet J; Mehran R
    JACC Cardiovasc Interv; 2011 Oct; 4(10):1119-28. PubMed ID: 22017938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of drug-eluting stents including the economic impact of late stent thrombosis.
    Filion KB; Roy AM; Baboushkin T; Rinfret S; Eisenberg MJ
    Am J Cardiol; 2009 Feb; 103(3):338-44. PubMed ID: 19166686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial.
    von Birgelen C; Basalus MW; Tandjung K; van Houwelingen KG; Stoel MG; Louwerenburg JH; Linssen GC; Saïd SA; Kleijne MA; Sen H; Löwik MM; van der Palen J; Verhorst PM; de Man FH
    J Am Coll Cardiol; 2012 Apr; 59(15):1350-61. PubMed ID: 22341737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprint stent in uncertain DES candidates study.
    Valgimigli M; Patialiakas A; Thury A; Colangelo S; Campo G; Tebaldi M; Ungi I; Tondi S; Roffi M; Menozzi A; de Cesare N; Garbo R; Meliga E; Testa L; Gabriel HM; Airoldi F; Ferlini M; Liistro F; Dellavalle A; Vranckx P; Briguori C
    Am Heart J; 2013 Nov; 166(5):831-8. PubMed ID: 24176438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study.
    Räber L; Magro M; Stefanini GG; Kalesan B; van Domburg RT; Onuma Y; Wenaweser P; Daemen J; Meier B; Jüni P; Serruys PW; Windecker S
    Circulation; 2012 Mar; 125(9):1110-21. PubMed ID: 22302840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.